RESEARCH JOURNAL
Every article traces back to published research. No hype, no therapeutic claims. Research-use-only framing — because integrity compounds.
A systematic look at the published evidence on BPC-157 and tendon healing — what the animal models demonstrate, where the human data stands, and why the gap between them matters.
Read article →BPC-157 drives angiogenesis. TB-500 drives cell migration. They target different phases of the repair cascade — and that's exactly why researchers combine them.
Read article →A 2026 retrospective study of 7,965 patients found tirzepatide causes 2x more lean mass loss than semaglutide at 12 months. But the full picture is more nuanced than the headline.
Read article →A COA is only as good as the tests it includes and the lab that ran them. Here's exactly what to look for — and what to run from.
Read article →TB-500 acts through actin sequestration and cell migration pathways — fundamentally different mechanisms from BPC-157. Here's what the published research demonstrates.
Read article →